Dapagliflozin Patient Satisfaction Survey
Study identifier:D1690R00026
ClinicalTrials.gov identifier:NCT02805283
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Direct to Patient Survey to Examine Treatment Satisfaction and Experience with Dapagliflozin Compared to Sulfonylureas
Medical condition
Diabetes Mellitus, Type 2
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
653
Study type
Observational
Age
N/A
Date
Study Start Date: 22 Jun 2016
Primary Completion Date: 29 Oct 2018
Study Completion Date: 29 Oct 2018
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Oct 2019 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Optum
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Dapagliflozin, dapagliflozin/met ER Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification. | - |
| Sulfonylurea Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification. | - |
Contacts
Investigators
Principal Investigator
Kelly Bell
AstraZeneca
